These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 22079830)
1. Transendocytosis is impaired in CADASIL-mutant NOTCH3. Watanabe-Hosomi A; Watanabe Y; Tanaka M; Nakagawa M; Mizuno T Exp Neurol; 2012 Jan; 233(1):303-11. PubMed ID: 22079830 [TBL] [Abstract][Full Text] [Related]
2. CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Peters N; Opherk C; Zacherle S; Capell A; Gempel P; Dichgans M Exp Cell Res; 2004 Oct; 299(2):454-64. PubMed ID: 15350543 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling Pathway. Joutel A; Monet M; Domenga V; Riant F; Tournier-Lasserve E Am J Hum Genet; 2004 Feb; 74(2):338-47. PubMed ID: 14714274 [TBL] [Abstract][Full Text] [Related]
4. Lunatic fringe promotes the aggregation of CADASIL NOTCH3 mutant proteins. Suzuki S; Hiura S; Mashiko T; Matsumoto T; Itoh M Biochem Biophys Res Commun; 2021 Jun; 557():302-308. PubMed ID: 33894418 [TBL] [Abstract][Full Text] [Related]
5. Determination of Blood NOTCH3 Extracellular Domain and Jagged-1 Levels in Healthy Subjects. Kim H; Jang B; Kim YJ; Choi JC Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142458 [TBL] [Abstract][Full Text] [Related]
6. The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo. Monet M; Domenga V; Lemaire B; Souilhol C; Langa F; Babinet C; Gridley T; Tournier-Lasserve E; Cohen-Tannoudji M; Joutel A Hum Mol Genet; 2007 Apr; 16(8):982-92. PubMed ID: 17331978 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept. Rutten JW; Dauwerse HG; Peters DJ; Goldfarb A; Venselaar H; Haffner C; van Ommen GJ; Aartsma-Rus AM; Lesnik Oberstein SA Brain; 2016 Apr; 139(Pt 4):1123-35. PubMed ID: 26912635 [TBL] [Abstract][Full Text] [Related]
8. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) associated with a novel C82R mutation in the NOTCH3 gene. Zea-Sevilla MA; Bermejo-Velasco P; Serrano-Heranz R; Calero M J Alzheimers Dis; 2015; 43(2):363-7. PubMed ID: 25096610 [TBL] [Abstract][Full Text] [Related]
9. Functional analysis of a recurrent missense mutation in Notch3 in CADASIL. Haritunians T; Chow T; De Lange RP; Nichols JT; Ghavimi D; Dorrani N; St Clair DM; Weinmaster G; Schanen C J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1242-8. PubMed ID: 16107360 [TBL] [Abstract][Full Text] [Related]
10. Progress to Clarify How Mizuta I; Nakao-Azuma Y; Yoshida H; Yamaguchi M; Mizuno T Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254727 [TBL] [Abstract][Full Text] [Related]
11. Putative role of specific JAG1 gene exons in modulating clinical features in patients with leukoencephalopathy. Ungaro C; Sprovieri T; Conforti FL; Muglia M; Patitucci A; Magariello A; Gabriele AL; Quattrone A; Mazzei R Neurosci Lett; 2007 May; 418(1):1-3. PubMed ID: 17368936 [TBL] [Abstract][Full Text] [Related]
12. Control of Notch-ligand endocytosis by ligand-receptor interaction. Hansson EM; Lanner F; Das D; Mutvei A; Marklund U; Ericson J; Farnebo F; Stumm G; Stenmark H; Andersson ER; Lendahl U J Cell Sci; 2010 Sep; 123(Pt 17):2931-42. PubMed ID: 20720151 [TBL] [Abstract][Full Text] [Related]
13. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Monet-Leprêtre M; Bardot B; Lemaire B; Domenga V; Godin O; Dichgans M; Tournier-Lasserve E; Cohen-Tannoudji M; Chabriat H; Joutel A Brain; 2009 Jun; 132(Pt 6):1601-12. PubMed ID: 19293235 [TBL] [Abstract][Full Text] [Related]
14. A CADASIL-mutated Notch 3 receptor exhibits impaired intracellular trafficking and maturation but normal ligand-induced signaling. Karlström H; Beatus P; Dannaeus K; Chapman G; Lendahl U; Lundkvist J Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17119-24. PubMed ID: 12482954 [TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization and cellular effects of CADASIL mutants of NOTCH3. Meng H; Zhang X; Yu G; Lee SJ; Chen YE; Prudovsky I; Wang MM PLoS One; 2012; 7(9):e44964. PubMed ID: 23028706 [TBL] [Abstract][Full Text] [Related]
16. The NOTCH3 score: a pre-clinical CADASIL biomarker in a novel human genomic NOTCH3 transgenic mouse model with early progressive vascular NOTCH3 accumulation. Rutten JW; Klever RR; Hegeman IM; Poole DS; Dauwerse HG; Broos LA; Breukel C; Aartsma-Rus AM; Verbeek JS; van der Weerd L; van Duinen SG; van den Maagdenberg AM; Lesnik Oberstein SA Acta Neuropathol Commun; 2015 Dec; 3():89. PubMed ID: 26715087 [TBL] [Abstract][Full Text] [Related]
18. CADASIL-causing mutations do not alter Notch3 receptor processing and activation. Low WC; Santa Y; Takahashi K; Tabira T; Kalaria RN Neuroreport; 2006 Jul; 17(10):945-9. PubMed ID: 16791082 [TBL] [Abstract][Full Text] [Related]
19. Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss-of-function mechanism. Cognat E; Baron-Menguy C; Domenga-Denier V; Cleophax S; Fouillade C; Monet-Leprêtre M; Dewerchin M; Joutel A Stroke; 2014 Mar; 45(3):842-9. PubMed ID: 24425116 [TBL] [Abstract][Full Text] [Related]